Filana Therapeutics (FLNA) Cash & Equivalents Growth (3y) (2013 - 2026)
Filana Therapeutics (FLNA) Cash & Equivalents Growth (3y) (2013 - 2026) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Equiv. Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 139.13 Bn | 131.28 Bn | 2.84 Bn | -15.41% |
| 2 | Regeneron Pharmaceuticals | 85.77 Bn | 77.77 Bn | 3.93 Bn | 8.23% |
| 3 | Argenx Se | 64.64 Bn | 59.46 Bn | 1.37 Bn | 47.78% |
| 4 | Moderna | 58.29 Bn | 53.16 Bn | 52.00 Mn | -23.18% |
| 5 | BeOne Medicines | 41.92 Bn | 36.82 Bn | 1.53 Bn | 14.34% |
| 6 | Alnylam Pharmaceuticals | 31.58 Bn | 28.28 Bn | 992.69 Mn | 37.45% |
| 7 | BioNTech SE | 28.12 Bn | 9.73 Bn | 668.28 Mn | -14.22% |
| 8 | Insmed | 27.39 Bn | 26.22 Bn | 358.27 Mn | -3.85% |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | -27.97% |
| 10 | Filana Therapeutics | 46.00 Mn | 46.00 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -21.12% |
| Mar 31, 2026 | -22.70% |
| Dec 31, 2025 | -21.97% |
| Sep 30, 2025 | -15.31% |
| Jun 30, 2025 | -17.10% |
| Mar 31, 2025 | -17.60% |
| Dec 31, 2024 | -18.03% |
| Sep 30, 2024 | -14.88% |
| Jun 30, 2024 | -9.35% |
| Mar 31, 2024 | -23.94% |
| Dec 31, 2023 | 9.01% |
| Sep 30, 2023 | 80.83% |
| Jun 30, 2023 | 88.24% |
| Mar 31, 2023 | 94.19% |
| Dec 31, 2022 | 105.74% |
| Sep 30, 2022 | 114.07% |
| Jun 30, 2022 | 119.96% |
| Mar 31, 2022 | 122.16% |
| Dec 31, 2021 | 127.57% |
| Sep 30, 2021 | 127.75% |